Internal Medicine, Pulmonary Disease · Ann Arbor, MI
NPI
1649219734
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
380 Parkland Plz
Ann Arbor, MI, 48103
Phone (734) 615-3217
Groups this clinician bills Medicare through
Medicare paid, 2024
$10K
202 services
Medicare patients, 2024
73
Average age 66
Drug cost, 2024
$2.7M
2,135 prescriptions
Company payments, 2025
$176K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Njira L Lugogo was code 99214 (office e&m - established), 50 times for 38 patients. In total Njira L Lugogo billed 202 services in 15 codes, and Medicare paid $10K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-05-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 50 | 38 | $67.03 | $3,351 |
| 99214 Office E&M - Established | Office | 47 | 35 | $65.65 | $3,085 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 33 | 27 | $13.14 | $434 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 15 | 14 | $12.26 | $184 |
By year: 2022 $11K for 194 services; 2023 $11K for 201 services; 2024 $10K for 202 services.
Medicare prescription drug claims, 2024
In 2024, the drug Njira L Lugogo prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 203 prescriptions and refills. In total Njira L Lugogo wrote 2,135 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 203 | 255 | 42 | $157K |
| Prednisone Generic | 170 | 212 | 52 | $892 |
| Tezspire Tezepelumab-Ekko | 168 | 172 | 21 | $736K |
| Montelukast Sodium Generic | 142 | 326 | 43 | $2,020 |
| Spiriva Respimat Tiotropium Bromide | 135 | 195 | 27 | $97K |
| Azithromycin Generic | 117 | 139 | 39 | $1,481 |
| Dupixent Syringe Dupilumab | 110 | 113 | Under 11 | $417K |
| Dupixent Pen Dupilumab | 110 | 114 | 14 | $421K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 87 | 95 | 39 | $2,430 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 87 | 137 | 23 | $16K |
| Fasenra Pen Benralizumab | 86 | 132 | 21 | $464K |
| Symbicort Budesonide/Formoterol Fumarate | 60 | 110 | 23 | $27K |
| Advair Hfa Fluticasone Propion/Salmeterol | 56 | 75 | 14 | $30K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 55 | 107 | 15 | $20K |
| Breo Ellipta Fluticasone/Vilanterol | 33 | 57 | Under 11 | $22K |
Brand drugs: 1,370 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Njira L Lugogo $176K ($143K in general payments such as food, travel and fees and $32K for research) from 15 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $50K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 51 | $50K |
| AstraZeneca UK Limited AZN | 13 | $38K |
| Genzyme Corporation SNY | 36 | $27K |
| Regeneron Pharmaceuticals, Inc. REGN | 23 | $19K |
| GlaxoSmithKline, LLC. GSK | 7 | $16K |
| Amgen Inc. AMGN | 7 | $11K |
| Chiesi USA, Inc. | 7 | $9,128 |
| Pfizer Inc. PFE | 2 | $3,125 |
| Incyte Corporation INCY | 1 | $1,260 |
| Abbvie Inc. ABBV | 1 | $575 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.